$NMRA 8-K/A SEC Filings

Filed On	Filing
11 Apr 2025	8-K/A: Departure/Election of Directors or Officers; Compensation On February 13, 2025, Neumora Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (as amended, the “Initial 8-K”) with the U.S. Securities and Exchange Commission disclosing, among other things, approval by the Board of...
21 Feb 2025	8-K/A: Departure/Election of Directors or Officers; Compensation Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.